These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38675792)

  • 1. Design and Characterization of a New Formulation for the Delivery of COVID-19-mRNA Vaccine to the Nasal Mucosa.
    Altay Benetti A; Tan EYZ; Chang ZW; Bae KH; Thwin MT; Muthuramalingam RPK; Liao KC; Wan Y; Ng LFP; Renia L; Liu J; Chen X; Yang YY; White KP; Pastorin G
    Vaccines (Basel); 2024 Apr; 12(4):. PubMed ID: 38675792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal immunization with the recombinant measles virus encoding the spike protein of SARS-CoV-2 confers protective immunity against COVID-19 in hamsters.
    Park SI; Park S; Lee K; Kwak HW; Kim YK; Park HJ; Bang YJ; Kim JY; Kim D; Seo KW; Lee SJ; Kim H; Kim Y; Kim DH; Park HJ; Jung SY; Ga E; Hwang J; Na W; Hong SH; Lee SM; Nam JH
    Vaccine; 2024 Jan; 42(2):69-74. PubMed ID: 38097457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of a silica nanoparticle-based SARS-CoV-2 vaccine in mice.
    Barbey C; Su J; Billmeier M; Stefan N; Bester R; Carnell G; Temperton N; Heeney J; Protzer U; Breunig M; Wagner R; Peterhoff D
    Eur J Pharm Biopharm; 2023 Nov; 192():41-55. PubMed ID: 37774890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
    Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
    Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid nanoparticle formulations for optimal RNA-based topical delivery to murine airways.
    Tam A; Kulkarni J; An K; Li L; Dorscheid DR; Singhera GK; Bernatchez P; Reid G; Chan K; Witzigmann D; Cullis PR; Sin DD; Lim CJ
    Eur J Pharm Sci; 2022 Sep; 176():106234. PubMed ID: 35688311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced mucosal immune responses and reduced viral load in the respiratory tract of ferrets to intranasal lipid nanoparticle-based SARS-CoV-2 proteins and mRNA vaccines.
    Boley PA; Lee CM; Schrock J; Yadav KK; Patil V; Suresh R; Lu S; Feng MM; Hanson J; Channappanavar R; Kenney SP; Renukaradhya GJ
    J Nanobiotechnology; 2023 Feb; 21(1):60. PubMed ID: 36814238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RBD decorated PLA nanoparticle admixture with aluminum hydroxide elicit robust and long lasting immune response against SARS-CoV-2.
    Meena J; Singhvi P; Srichandan S; Dandotiya J; Verma J; Singh M; Ahuja R; Panwar N; Wani TQ; Khatri R; Siddiqui G; Gupta A; Samal S; Panda AK
    Eur J Pharm Biopharm; 2022 Jul; 176():43-53. PubMed ID: 35589003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A bacterial extracellular vesicle-based intranasal vaccine against SARS-CoV-2 protects against disease and elicits neutralizing antibodies to wild-type and Delta variants.
    Jiang L; Driedonks TAP; Jong WSP; Dhakal S; Bart van den Berg van Saparoea H; Sitaras I; Zhou R; Caputo C; Littlefield K; Lowman M; Chen M; Lima G; Gololobova O; Smith B; Mahairaki V; Riley Richardson M; Mulka KR; Lane AP; Klein SL; Pekosz A; Brayton C; Mankowski JL; Luirink J; Villano JS; Witwer KW
    J Extracell Vesicles; 2022 Mar; 11(3):e12192. PubMed ID: 35289114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine.
    Zhu J; Jain S; Sha J; Batra H; Ananthaswamy N; Kilgore PB; Hendrix EK; Hosakote YM; Wu X; Olano JP; Kayode A; Galindo CL; Banga S; Drelich A; Tat V; Tseng CK; Chopra AK; Rao VB
    mBio; 2022 Aug; 13(4):e0182222. PubMed ID: 35900097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design of SARS-CoV-2 hFc-Conjugated Receptor-Binding Domain mRNA Vaccine Delivered
    Elia U; Ramishetti S; Rosenfeld R; Dammes N; Bar-Haim E; Naidu GS; Makdasi E; Yahalom-Ronen Y; Tamir H; Paran N; Cohen O; Peer D
    ACS Nano; 2021 Jun; 15(6):9627-9637. PubMed ID: 33480671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of Systemic and Mucosal Humoral Immune Responses to an Adjuvanted Intranasal SARS-CoV-2 Protein Subunit Vaccine Candidate in Mice.
    Maltseva M; Galipeau Y; Renner TM; Deschatelets L; Durocher Y; Akache B; Langlois MA
    Vaccines (Basel); 2022 Dec; 11(1):. PubMed ID: 36679875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The investigation of mRNA vaccines formulated in liposomes administrated in multiple routes against SARS-CoV-2.
    Huang H; Zhang C; Yang S; Xiao W; Zheng Q; Song X
    J Control Release; 2021 Jul; 335():449-456. PubMed ID: 34029632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gold-Nanostar-Chitosan-Mediated Delivery of SARS-CoV-2 DNA Vaccine for Respiratory Mucosal Immunization: Development and Proof-of-Principle.
    Kumar US; Afjei R; Ferrara K; Massoud TF; Paulmurugan R
    ACS Nano; 2021 Nov; 15(11):17582-17601. PubMed ID: 34705425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid Nanoparticle-Based Inhibitors for SARS-CoV-2 Host Cell Infection.
    Yathindranath V; Safa N; Tomczyk MM; Dolinsky V; Miller DW
    Int J Nanomedicine; 2024; 19():3087-3108. PubMed ID: 38562613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trivalent mRNA Vaccine against SARS-CoV-2 and Variants with Effective Immunization.
    Wang J; Zhang Y; Liu C; Zha W; Dong S; Wang Y; Jiang Y; Xing H; Li X
    Mol Pharm; 2023 Oct; 20(10):4971-4983. PubMed ID: 37699256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
    Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
    Elife; 2022 Jan; 11():. PubMed ID: 35072628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ferritin-binding and ubiquitination-modified mRNA vaccines induce potent immune responses and protective efficacy against SARS-CoV-2.
    Yu T; Zhang C; Xing J; Zhang T; Xu Z; Di Y; Yang S; Jiang R; Tang J; Zhuang X; Jin N; Tian M
    Int Immunopharmacol; 2024 Mar; 129():111630. PubMed ID: 38320355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasal Delivery of Thermostable Subunit Vaccine for Cross-Reactive Mucosal and Systemic Antibody Responses Against SARS-CoV-2.
    Nguyen KG; Mantooth SM; Vrabel MR; Zaharoff DA
    Front Immunol; 2022; 13():858904. PubMed ID: 35592324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal VLP-RBD vaccine adjuvanted with BECC470 confers immunity against Delta SARS-CoV-2 challenge in K18-hACE2-mice.
    Lee KS; Rader NA; Miller-Stump OA; Cooper M; Wong TY; Shahrier Amin M; Barbier M; Bevere JR; Ernst RK; Heath Damron F
    Vaccine; 2023 Jul; 41(34):5003-5017. PubMed ID: 37407405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A SARS-CoV-2 RBD vaccine fused to the chemokine MIP-3α elicits sustained murine antibody responses over 12 months and enhanced lung T-cell responses.
    Gordy JT; Hui Y; Schill C; Wang T; Chen F; Fessler K; Meza J; Li Y; Taylor AD; Bates RE; Karakousis PC; Pekosz A; Sachithanandham J; Li M; Karanika S; Markham RB
    Front Immunol; 2024; 15():1292059. PubMed ID: 38370404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.